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Background: P-selectin inhibition with protein therapeutics such as antibodies or soluble ligands given intravenously can
decrease thrombosis in a mouse ligation model of venous thrombosis. In this study, we hypothesized that oral inhibition
of P selectin with a novel oral nonprotein inhibitor (PSI-697) would decrease thrombosis and circulating microparticle
populations. This study evaluated the effects on thrombosis and circulating microparticle populations in this murine
venous thrombosis model.
Methods:Mice underwent inferior vena cava ligation to induce thrombosis. Mice with high circulating level of P selectin,
Delta Cytoplasmic Tail (^CT), mice gene-deleted for both E- and P-selectin knockout (EPKO), and wild-type C57BL/6
mice (WT) were studied without and with administration of PSI-697 in food (100 mg/kg daily) from 2 days before
thrombosis until the end of the study. Animals were killed 2 and 6 days later. Evaluations included thrombus weight
(TW), vein wall morphometrics, microparticle quantification by using fluorescence-activated cell sorter analysis, and vein
wall enzyme-linked immunosorbent assays for interleukin (IL)-10, P selectin, and monocyte chemotactic protein 1.
Results: PSI-697 significantly decreased TW in WT and ^CT mice, with a treated vs nontreated TW of 132  24 vs 228
 29 104 g (P .014) and 166 19 vs 281 16 104 g (P .001), respectively. At day 6, the effect was significant
only in the ^CT group (P < .05). Drug therapy at day 2 significantly increased vein wall monocytes in WT mice and
increased monocytes and total inflammatory cells in ^CT animals. A significant decrease in neutrophils and total
inflammatory cells was seen in EPKO mice at day 2 with therapy. Therapy significantly increased platelet-derived
microparticles and total microparticles in ^CTmice on day 2. Changes in treatedWT and treated EPKO animals were not
significant compared with respective vehicle treatments at day 2. On day 6, therapy significantly decreased total
microparticles in EPKO animals. Vein wall expression of IL-10 increased in all groups with therapy at day 2 (n 18) and
was significantly increased in WT (2687.5  903 pg/mL vs 636  108 pg/mL total protein; P  .038) and ^CT (2078
 295 pg/mL vs 432  62 pg/mL total protein; P  .001) mice. Therapy significantly decreased vein wall P selectin,
monocyte chemotactic protein 1, and IL-10 levels at day 6.
Conclusions: PSI-697 decreased thrombosis. P-selectin inhibition allowed vein wall inflammatory cell extravasation in this
model of complete ligation. Circulatingmicroparticles (platelet-derivedmicroparticles and total microparticles) increased
with P-selectin inhibition, possibly because of decreased consumption into the thrombus. In summary, the oral
administration of an inhibitor to P selectin provides significant TW reduction. (J Vasc Surg 2005;42:329-36.)
Clinical Relevance: Deep venous thrombosis is a significant national health problem in the general population. The average
annual incidence of deep venous thrombosis is approximately 250,000 cases per year. The selectin family of adhesionmolecules
is thought to be largely responsible for the initial attachment and rolling of leukocytes on stimulated vascular endothelium.
Recent studies have explored the possible therapeutic implications of P-selectin inhibition tomodulate venous thrombosis. For
example, prophylactic dosing of a recombinant P-selectin ligand decreases venous thrombosis in a dose-dependent fashion in
both feline and nonhuman primate animalmodels. Additionally, treatment of 2-day iliac thrombi with a recombinant protein,
P-selectin inhibitor, significantly improves vein reopening in nonhuman primates. It is interesting to note that P-selectin
inhibition decreases thrombosis without adverse anticoagulation. On the basis of the results from these previous studies, the
use of P-selectin antagonism is a logical therapeutic approach to treat venous thrombosis. All inhibitors developed to date are
either proteins or small molecules with low oral bioavailability that require intravenous or subcutaneous injection. This study
evaluates, for the first time, a novel orally bioavailable inhibitor of P-selectin (PSI-697).Deep venous thrombosis is a significant national health
problem in the general population. The average annual
incidence of deep venous thrombosis is approximately
From the Section of Vascular Surgery, Jobst Vascular Research Laborato-
ries,a and Unit for Laboratory Animal Medicine,b University of Michigan
Medical Center, Ann Arbor, and Wyeth Research, Cambridge.c
Supported by National Institutes of Health grant RO1HL 70766 (T.W.W.)
and Wyeth Research.
Competition of interest: none.
Presented at the Seventeenth Annual Meeting of the American Venous
Forum, San Diego, Calif, Feb 12, 2005.250,000 cases per year.1-3 The selectin family of adhesion
molecules is thought to be largely responsible for the initial
attachment and rolling of leukocytes on stimulated vascular
endothelium. This family consists of P selectin expressed on
activated platelets and activated endothelium, E selectin
Reprint requests: Daniel D. Myers, Jr, DVM, MPH, 1150 W Medical
Center Dr, Dock 6, MSRB II A570D, Ann Arbor, MI 48109-0654
(e-mail: ddmyers@umich.edu).
0741-5214/$30.00
Copyright © 2005 by The Society for Vascular Surgery.
doi:10.1016/j.jvs.2005.04.045
329
JOURNAL OF VASCULAR SURGERY
August 2005330 Myers et alexpressed on activated vascular endothelium, and L selectin
expressed on the surface of neutrophils. All selectins have
been shown to recognize the sialyl Lewisx carbohydrate
ligands. The adhesion molecule P selectin, which is present
in platelet -granules and endothelial cell Weible-Palade
bodies,4 is expressed on the surface of these cells early
during venous thrombosis and promotes vein wall inflam-
mation in multiple animal models.5
The ligand for P selectin is a glycoprotein expressed on
the surfaces of most hematopoietic cells termed P-selectin
glycoprotein ligand (PSGL)-1. PSGL-1 is a homodimeric
mucin associated with the adhesion interactions that are
responsible for the initial rolling of neutrophils along stim-
ulated vascular endothelium and the formation of platelet/
leukocyte complexes on the vascular surface and in the
circulation.6 This ligand has a high affinity for P selectin and
a lesser affinity for E and L selectin. P selectin is upregulated
rapidly and downregulated within minutes to hours.
We have confirmed the importance of inflammation
and selectins in venous thrombosis by using rodent models.
In mice, vein wall neutrophils are significantly increased
above sham control animals at day 2 after thrombosis,
monocytes are significantly increased above sham controls
at day 6 after thrombosis, and total inflammatory cell
counts are significantly increased at both time points. Vein
wall protein determination showed that P selectin was
upregulated as early as 6 hours after thrombus induction,
whereas marked protein increases of E selectin occurred 6
days after thrombosis. P selectin remained increased
through day 6 after thrombosis, and messenger RNA activ-
ity preceded protein increases.5 Also, mice gene-deleted for
both E and P selectin have significant decreases in throm-
bus fibrin staining and weight when compared with wild-
type (WT) control animals at both 2 and 6 days after
thrombosis.7 Recent studies have explored the possible
therapeutic implications of P-selectin inhibition to modu-
late venous thrombosis. For example, the administration of
a recombinant P-selectin ligand before the thrombogenic
event decreased venous thrombosis in a dose-dependent
fashion in both feline and nonhuman primate animal mod-
els.8,9 Additionally, treatment of 2-day-old iliac thrombi
with the same recombinant P-selectin ligand significantly
improved vein reopening in nonhuman primates without
adverse anticoagulation.10
Research attention has been focused on the roles P
selectin may have in influencing the formation of circulat-
ing microparticles (MPs). MPs are described as fragments
(1 m) of phospholipids from cell membranes that have
hypercoagulable properties. Previous studies suggest that
MPs are important in early venous thrombogenesis and
that these MPs (with membrane-bound tissue factor) are
incorporated into the developing thrombus.11-13 In a re-
cent study, we noted that mice with high circulating levels
of soluble P selectin formed thrombi, whereas animals with
gene deletions of both E selectin and P selectin (EPKO)
formed smaller thrombi, and that MPs (derived more from
leukocytes than platelets) were associated with early throm-
bogenesis.14On the basis of the results from these previous studies,
the use of P-selectin antagonism is a logical therapeutic
approach to treat venous thrombosis. All inhibitors devel-
oped to date are either proteins or small molecules with low
oral bioavailability that require intravenous or subcutane-
ous injection. This study evaluates, for the first time, a novel
orally bioavailable inhibitor of P selectin (PSI-697). To
evaluate this novel oral compound, mice underwent com-
plete stasis-induced venous thrombosis. In this study, we
hypothesized that blocking P selectin with this new orally
available compound would decrease thrombosis and in-
flammation while modulating the effects of prothombotic
MPs.
METHODS
Mouse inferior vena cava stasis model. Male mice
(Mus musculus; n 432) weighing 20 to 30 g made up the
study population. All but 10 mice were anesthetized with
isoflurane gas, a midline laparotomy was performed, and
the inferior vena cava (IVC) was directly approached and
ligated with 7-0 Prolene (Ethicon, Inc, Somerville, NJ)
sutures just below the renal veins, with ligation of large
venous side branches.5 The 10 nonoperated animals were
used to assess the effectiveness of the P-selectin inhibitor.
Mice were evaluated at selected time points after IVC
ligation, including day 2 and day 6. This study used mouse
groups treated with and without PSI-697 in food: WT
C57BL/6 controls (Harlan, Indianapolis, IN), hypercoag-
ulable mice with high levels of soluble P selectin Delta
Cytoplasmic Tail (^CT); (Denisa Wagner, Cambridge,
MA),11,15 and EPKO mice (Daniel Bullard, University of
Alabama, AL).16,17
P-selectin inhibition. The small molecule inhibitor of
P-selectin (PSI-697; Wyeth Research, Cambridge, MA) is
an orally available noncarbohydrate and nonantibody in-
hibitor of P selectin. This compound has been demon-
strated in vitro to disrupt the binding of P selectin to its
ligand PSGL-1 and to reduce white cell rolling in the
microvasculature of mice. From studies in mice, this drug
seems to enter the bloodstream within 1 hour after con-
sumption in chow (unpublished data, Wyeth Research).
Mice (five per cage) were fed either a powdered vehicle
control rodent chow or rodent chow formulated with
PSI-697 (drug-enhanced chow, 100 mg · kg1 · d1
orally) ad libitum. The PSI-697 animal groups were admin-
istered vehicle control chow for 5 days of chow acclimation
and were then switched to PSI-697–containing chow (1.0
mg of PSI-697 per gram of chow) 2 days before thrombosis
until the end of each experiment. Vehicle control chow
animals remained on this diet for the full length of the
study. Control animals consumed 126  12 g compared
with 136  8 g consumed by mice with PSI-697 therapy
over the duration of the study. Additionally, we measured
weight changes in experimental animals. On average, WT
mice, ^CT mice, and EPKO mice weighed 24.5  0.6 g,
22.4  0.7 g, and 22.5  1.0 g, respectively, before
thrombosis. Six days after thrombosis, the change of animal
weight in experimental groups was recorded as follows: WT
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(1.8% increase); and EPKO mice, 21.5  0.4 g (0.5%
decrease) with PSI-697 therapy. All powdered chow for-
mulations were made available to mice in a 16-ounce
powdered food feeder (model PFF16D; Allentown Caging
Equipment Co, Inc, Allentown, NJ).
Thrombus weight. Groups of mice were analyzed for
thrombus weight (TW) at each time point. This technique
is an indirect measure of thrombus content. At death, the
IVC and its associated thrombus were removed and
weighed.
Vein wall morphometrics. Veins were examined un-
der high-power oil-immersion light microscopy. Sections
were stained with hematoxylin and eosin from paraffin-
embedded tissues. Five representative high-power fields
(HPFs; oil immersion; magnification, 1000) were exam-
ined around the vein wall, and the cell count of the vein wall
was analyzed manually by a study-blinded veterinary pa-
thologist. Cells were identified as neutrophils, monocyte/
macrophages, or lymphocytes according to standard histo-
logic criteria, including nuclear size, cytoplasmic content,
and total cell size for the inflammatory cell types.5,18 Re-
sults from the five HPFs were added together for each
section studied, and the mean  SEM were calculated for
each group.
Murine platelet and leukocyte MP analysis. Mouse
groups were evaluated for MP populations at days 2 and 6
after thrombosis. Whole blood (0.8 mL) was removed from
the mice by intracardiac puncture with a syringe primed
with 10% acid citrate dextrose. The whole blood was then
centrifuged to produce platelet poor plasma (PPP). PPP
samples were incubated with antibodies that stained leuko-
cytes and platelets. These included rat anti-murine phyco-
erythrin (red; CD11b; stains leukocytes) 10 g/mL
(Chemicon International, Temecula, CA) and rat anti-
murine fluorescein isothiocyanate (green; CD41; stains
platelets) 5 g/mL (BD Pharmingen, San Diego, CA).14
Flow cytometry analysis was performed to identify MP
populations. For MP quantification, a known quantity
(250,000) of 3.0- to 3.4-m-diameter beads (SPHERO;
BD Pharmingen) was added to each fixed sample before
fluorescence-activated cell sorter analysis, and acquisition
was stopped after 50,000 beads were counted in the R-1
bead gate. The diameter of these beads allowed for discrim-
ination from the MP population on light scatter and was
counted with a separate bead gate. The total MP number
per 200 L of PPP was then calculated. The quantitative
MP data were divided into the following groups: leukocyte-
derived MPs (LMPs), platelet-derived MPs (PMPs), and
total MPs (TMPs).
Vein wall enzyme-linked immunosorbent assay.
Protein levels of interleukin (IL)-10, P selectin, and the
cytokine monocyte chemotactic protein 1 were measured
from vein wall homogenates at 2 and 6 days after throm-
bosis. All enzyme-linked immunosorbent assay (ELISA)
samples were run in duplicate according to themanufacturer’s
suggestions. ELISA plates were read on a Plate Reader
Elx808 (Biotek, Winooski, VT) at a wavelength of 450 nm,and levels of total protein were reported in picograms per
milliliter.
Statistical evaluation and animal use. Statistical
analysis included analysis of variance, Mann-Whitney rank
sum tests, and unpaired Student t tests for parametric data
(SPSS SigmaStat 2.0; Leesburg, Va). Significance was de-
fined as P  .05. The health status of all animals was
monitored by use of a sentinel program, and all animals
were free of pathogens. All mice were housed and cared for
by the University of Michigan Unit for Laboratory Animal
Medicine. The University of Michigan is an American
Association for Accreditation of Laboratory Animal Care–
accredited facility under the direction of a veterinarian
according to the Principles of Laboratory Animal Care
(formulated by the National Society for Medical Research)
and the Guide for the Care and Use of Laboratory Animals
(National Academy of Sciences, 1996). The University of
Michigan Committee on Use and Care of Animals ap-
proved this research protocol.
RESULTS
PSI-697 decreases thrombosis. In this study, PSI-
697 significantly decreased TW in both WT (n  20) and
^CT (n  19) mice compared with untreated animals 2
days after thrombosis (WT: 132 24 vs 228 29 104
g; P  .014; ^CT: 166  19 vs 281  16  104 g; P 
.001; Fig 1, A). At day 6, the significant decrease in TWwas
noted only in the ^CT (n  20) mice (204  17 vs 274 
21  104 g; P  .012; Fig 1, B). Conversely, the EPKO (n
 14) mouse group with drug showed a slight decrease in
TW at day 2, but this was not significant (Fig 1, A).
Additionally, the evaluation of plasma samples from exper-
imental mice showed that mice did receive therapeutic
concentrations of the compound during the study (1000
ng/mL). It is important to note that no obvious bleeding
or wound healing abnormality was noted in any of the
animals, either treated or control.
The percentage decrease in TW between animals with
drug therapy vs without drug therapy was also evaluated (n
 232; total number of animals with and without drug).
WT animals (n  20) with drug showed a significant 42%
decrease in TW at day 2 when compared with WT animals
(n 20) without drug therapy (P .014). Mice with high
circulating levels of P selectin (^CT) with drug therapy (n
 19) showed a 41% decrease in TW vs without drug (n
18) at day 2 (P  .001) and showed a 26% decrease in TW
with drug (n 20) vs without drug (n 19) at day 6 (P 
.012; Table I).
To elucidate the effects of the small molecule inhibitor
of P selectin, we evaluated only the subset of experimental
animals that were positive for thrombosis (n  215; total
number of animals with and without drug evaluated). Both
the WT (n  20) and EPKO (n  20) groups showed
significant decreases in TW in animals administered drug vs
without drug therapy at day 2 only (34% and 42%, P .042
and P  .035, respectively). The ^CT mice had significant
decreases in TW noted at both day 2 (n 17) and day 6 (n
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and P  .021, respectively; Table II).
PSI-697 increases vein wall inflammatory cell
populations. Drug treatment at day 2 significantly in-
creased vein wall monocytes in WT mice (30  1 vs 11 1
cells per 5HPFs; P .001) and increasedmonocytes (44
6 vs 11  3 cells per 5 HPFs; P  .001) and total
inflammatory cells in ^CT animals (144  14 vs 54  13
Fig 1. A. Small molecule inhibition of P selectin (PSI-697) sig-
nificantly decreased thrombus weight in the wild-type (WT) and
Delta Cytoplasmic Tail (^CT) groups at day 2. CTR, Control
without drug; EPKO,mice gene-deleted for both E and P selectin.
B, Only the ^CT mouse group with drug therapy showed a
significant decrease in thrombosis at day 6.
Table I. Percentage decrease in thrombus weight with
drug versus without drug in all experimental animals
Mouse group Day 2 Day 6
WT (n  85) 42% (P  .014) 18%
^CT (n  76) 41% (P  .001) 26% (P  .012)
EPKO (n  71) 42% 2%
WT,Wild-type; ^CT, Delta Cytoplasmic Tail; EPKO,mice gene-deleted for
both E and P selectin.cells per 5 HPFs; P  .002) when compared with animalsgiven vehicle control. A significant decrease in neutrophils
(16.5  7 vs 41  5 cells per 5 HPFs; P  .028) and total
inflammatory cells (32.5  10 vs 60  5 cells per 5 HPFs;
P  .021) was seen in EPKO mice at day 2 with drug
therapy vs vehicle control animals (Fig 2, A). For example,
hematoxylin and eosin staining showed decreased inflam-
matory cells in vein endothelium and adventitial layers 2
days after thrombosis in the ^CT vehicle control mouse
group, whereas with drug therapy, a significant increase in
Table II. Percentage decrease in thrombus weight with
drug versus without drug (only animals with inferior vena
cava thrombus)
Mouse group Day 2 Day 6
WT (n  76) 34% (P  .042) 14%
^CT (n  73) 35% (P  .001) 22% (P  .021)
EPKO (n  66) 42% (P  .035) 4% (increase)
WT,Wild-type; ^CT, Delta Cytoplasmic Tail; EPKO, mice gene-deleted for
both E and P selectin.
Fig 2. A.Drug treatment at day 2 significantly increased vein wall
inflammatory cell extravasation in wild-type (WT) and Delta Cy-
toplasmic Tail (^CT) animals, with increased thrombus burden.
Animals deficient in selectins had significantly decreased vein wall
inflammatory cell extravasation at day 2. NEUT, Neutrophils;
MONO, mononuclear cells; TC, total inflammatory cells; CTR,
control without drug; PSI, with PSI-697; EPKO, mice gene-
deleted for both E and P selectin;HPF, high-power field. B,Only
the ^CT group with PSI-697 therapy showed significant increases
in vein wall inflammatory cells at day 6.vein wall inflammatory cells was noted (Fig 3). On day 6, only
s). (B
PSI-6
E an
E an
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cells with drug therapy vs vehicle controls (Fig 2, B).
PSI-697 influences MP populations during
thrombosis. TheMP data involve quantitative assessment
of MP numbers and are divided into LMPs, PMPs, and
TMPs. In control nonthrombosed animals, PSI-697 effec-
tively decreased PMPs and TMPs (data not shown). This
attests to the effectiveness of the drug.
In animals that had undergone thrombosis, we evalu-
ated the effect of the drug on MP subtypes. At day 2,
P-selectin inhibition caused a significant increase in PMPs
with drug vs without drug in ^CT mice (444,248 
137,594 vs 72,451  17,313 MPs per 200 L of PPP; P 
.008; Table III). PSI-697 therapy also caused a significant
increase in TMPs in ^CT mice with drug compared with
Fig 3. Hematoxylin and eosin staining showed decrease
layers 2 days after thrombosis in a Delta Cytoplasmic T
prominent inflammatory cells aligned at the vein wall/
increase in vein wall inflammatory cells was noted in the ^
depict mononuclear cells; long arrows depict neutrophil
Table III. Day 2 microparticles
Group PMP CTR PMP PSI 
WT (n  9) 88,987 153,461 
^CT (n  10) 72,451 444,248 (P  .008)
EPKO (n  10) 234,607 195,315 
Data are microparticles per 200 L.
PMP, Platelet-derived microparticle; CTR, control without drug; PSI, with
wild-type; ^CT, Delta Cytoplasmic Tail; EPKO, mice gene-deleted for both
Table IV. Day 6 microparticles
Group PMP CTR PMP PSI LMP C
WT (n  11) 578,415 284,089 72
^CT (n  9) 331,508 657,923 23,6
EPKO (n  10) 362,322 250,393 21,5
Data are microparticles per 200 L.
PMP, Platelet-derived microparticle; CTR, control without drug; PSI, with
wild-type; ^CT, Delta Cytoplasmic Tail; EPKO, mice gene-deleted for both^CT mice without drug therapy (838,162  153,556 vs425,050  24,621 MPs per 200 L of PPP; P  .02). A
similar nonsignificant increase in PMPs and TMPs was
noted in WT animals, whereas animals with the lowest TW
(EPKO) revealed an opposite effect. The increase inMPs in
those animals with the greatest TW is consistent with a
proposed decrease in MP consumption into the thrombus
with drug therapy.
At day 6, drug therapy significantly decreased TMPs in
EPKO (643,822  72,303 vs 970,156  82,748 MPs per
200 L of PPP; P  .018; Table IV). Regarding LMPs,
drug therapy had little effect on day 2 and had no consistent
effect on day 6.
PSI-697 increases vessel wall IL-10. Drug therapy
increased vein wall expression of the anti-inflammatory
IL-10 in all groups treated with the small molecule inhibi-
ammatory cells in vein wall endothelium and adventitial
^CT) mouse without drug. Note that this animal had
bus interface. (A) With drug treatment, a significant
ouse at day 2 (original magnification,80; short arrows
) CTR, Control without drug; PSI, with PSI-697.
 CTR LMP PSI TMP CTR TMP PSI
810 1735 484,954 591,353
026 2326 425,050 838,162 (P  .02)
636 4752 683,078 577,855
97; LMP, leukocyte-derived microparticle; TMP, total microparticles; WT,
d P selectin.
LMP PSI TMP CTR TMP PSI
17,326 1,008,502 793,217
4028 733,765 1,165,112
6721 970,156 643,822 (P  .018)
97; LMP, leukocyte-derived microparticle; TMP, total microparticles; WT,
d P selectin.d infl
ail (
throm
CTmLMP
1
2
3TR
00
33
09
PSI-6tor to P selectin at day 2 (n  18). IL-10 measured in the
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903 pg/mL vs 636  108 pg/mL; P  .038) and ^CT
mice (2078 295 pg/mL vs 432 62 pg/mL; P .001)
administered drug compared with animals not given drug.
Drug therapy significantly decreased vein wall protein levels
of P selectin (7167 202 pg/mL vs 6258 248 pg/mL;
P .022) and IL-10 (2834 413 pg/mL vs 1473 160
pg/mL; P  .016) in ^CT mice and decreased P selectin
(670  107 pg/mL vs 168  65 pg/mL; P  .011) and
monocyte chemotactic protein 1 (116  22 pg/mL vs 16
 8 pg/mL; P  .019) in EPKO mice at day 6 (Fig 4).
DISCUSSION
The need for the development of new therapies that
Fig 4. A. The anti-inflammatory cytokine IL-10 was significantly
upregulated in wild-type (WT) and Delta Cytoplasmic Tail (^CT)
animals at day 2 treated with the small molecule inhibitor of P
selectin vs animals without drug. P selectin (Psel), monocyte
chemotactic protein 1 (MCP-1), and interleukin 10 (IL-10) were
measured from vein wall homogenates at 2 and 6 days after
thrombosis. CTR, Control without drug; PSI, with PSI-697;
EPKO, mice gene-deleted for both E and P selectin; ELISA,
enzyme-linked immunosorbent assay. B, Significant decreases in
protein expression were noted between the groups at day 6. Psel,
MCP-1, and IL-10 were measured from vein wall homogenates at
2 and 6 days after thrombosis.decrease thrombosis without adverse effects on hemostasisthat increase bleeding potential has become a major re-
search focus. The purpose of this study was to determine
the effects PSI-697, a novel oral inhibitor of P selectin.
Prophylaxis with an oral inhibitor of P selectin can
significantly decrease thrombosis (TW) at both early (day
2) and later (day 6) time points in our mouse model of
stasis-induced complete venous thrombosis. To evaluate
this oral compound, mice with high plasma levels of soluble
P selectin,11,15 EPKO mice,16,17 and WT C57BL/6 mice
were compared by using a complete stasis model of venous
thrombosis. The small molecule inhibitor in this study
significantly decreased TW in the ^CT and WT groups at
the early day 2 time point. At day 6, the effect was less
pronounced in WT mice but was still significant in the ^CT
mouse group. Of interest, mice deficient in selectins
(EPKO) demonstrated a decrease in thrombosis at day 2.
We would expect no effect in EPKOmice if the mechanism
of the small molecule inhibitor were only P selectin medi-
ated. The finding of a decrease in thrombosis in animals
devoid of E and P selectin at day 2 suggests that the drug
has other effects, yet to be identified, at this early time
point. We have shown in a previous study that mice defi-
cient in both E and P selectin have a decreased thrombus
burden and inflammatory cells 2 days after total blood
stasis, but that these gradually increase over time.5 This
suggests that E and P selectin–independent receptor/li-
gand interactions are active during chronic thrombosis.17
Vein wall inflammatory cell populations (morphomet-
rics) showed an inverse relationship when compared with
TW. WT and ^CT mice during thrombosis showed an
increase in vein wall neutrophils, monocytes, and total
inflammatory cells extravasating through the vein wall in
mice treated with PSI-697. This same population of mice
showed decreases in thrombosis when compared with mice
of the same strain given vehicle chow only, without drug.
Recent investigations have indicated that venous thrombi
in rats after induced neutropenia were larger and more
fibrotic and showed decreased resolution compared with
controls.19 Although one of the major roles of inflamma-
tory cells is the initiation of thrombus formation, neutro-
phils also possess cellular mediators, such as plasminogen
activator and elastase, that may prove to be thrombolytic
after the thrombus has formed.19,20 Additionally, mono-
cytes have been implicated in thrombus recanalization.21-24
In contrast, experimental mice that were deficient in both E
and P selectin had the least thrombus burden both with and
without drug and vein wall inflammatory cell populations.
Past studies have indicated that mice deficient in endothe-
lial selectin activity (EPKO) have diminished leukocyte
rolling and extravasation.25
The adhesionmolecule P selectin, once activated by the
stimulation of vascular endothelium, promotes P selectin/
PSGL-1 binding interactions, which lead to endothelial
cell/leukocyte, leukocyte/leukocyte, leukocyte/platelet,
and circulating MP formation. The interaction between
selectins and their leukocyte receptors stimulates fibrin
formation.26 Procoagulant MPs are recruited to the area of
thrombosis,27 where they amplify coagulation via tissue
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platelets, and leukocytes in the developing thrombus27 and
the contribution of P selectin to leukocyte/platelet inter-
actions that generate tissue factor33,34 support this scheme
of thrombogenesis.35
Notably, a recent investigation using intravital micros-
copy in a mouse model of arterial thrombosis showed that
circulating MPs with membrane-bound tissue factor do in
fact become incorporated into the developing thrombus
immediately after thrombus induction.13 We believe that
the incorporation of MPs is aided by the large amount of
IVC thrombosis in our experimental animals compared
with their overall body size.
In nonthrombosed animals, the small molecule inhibi-
tor effectively decreasedMPs, thus indicating that the small
molecule inhibitor of P selectin was effective in blocking P
selectin/PSGL-1 binding. The consumption of MPs noted
with thrombosis was effectively reversed by PSI-697. In
mice with the largest thrombi (^CT and WT), these MPs
were increased with drug therapy. This is likely due to a
reversal of the consumption of these MPs in the clot by the
drug, as noted in thrombosed animals without the benefit
of the compound. In the animals with fewer thrombi
(EPKO), the opposite effect was noted—that is, the MPs
were decreased in mice given the small molecule inhibitor
of P selectin. MPs from leukocyte origin were minimally
affected at day 2.
Finally, we evaluated the effect the small molecule
inhibitor of P selectin had on IL-10 in vein wall after
thrombosis in mice with and without the drug. The
amount of anti-inflammatory cytokine IL-10 measured in
the vein wall was significantly increased in WT and ^CT
animals at day 2 compared with nontreated animals. This
increase in IL-10 may suggest another possible mechanism
for the effectiveness of the therapy, because IL-10 has been
found to decrease thrombosis in our rodent model and has
been associated with decreased E- and P-selectin expres-
sion.36 The ELISA data showed a trend toward high P-
selectin upregulation at the early time points during throm-
bosis in this study. Notably, the EPKO animals had
minimal P-selectin expression in this study, and this was
expected.
In this study, we did not formally evaluate coagulation
tests. However, there were no obvious bleeding complica-
tions in the animals treated with PSI-697. We will evaluate
coagulation tests in further studies in other models. The
potential advantages of PSI-697 include its ability to be
administered orally and its reduction in thrombosis without
any adverse effects on the coagulation system and associ-
ated bleeding.
CONCLUSION
In this study, the orally available small molecule inhib-
itor of P selectin, PSI-697, significantly decreased throm-
bosis at the early time point in a mouse model of venous
thrombosis. P-selectin inhibition did allow for vein wall
inflammatory cell extravasation. Circulating MPs (PMPs
and TMPs) increased with P-selectin receptor inhibition,possibly because of decreased consumption into the throm-
bus. Finally, with treatment, the anti-inflammatory cyto-
kine IL-10 was significantly increased in the vein wall. In
summary, we have demonstrated for the first time that the
oral administration of a P-selectin inhibitor decreases
thrombosis in an animal model of stasis-induced venous
thrombosis formation. Such oral administration has poten-
tial significant advantages over intravenous or subcutane-
ous administration.
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